These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 22444787)
21. Fingolimod for the treatment of relapsing multiple sclerosis. Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700 [TBL] [Abstract][Full Text] [Related]
22. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746 [TBL] [Abstract][Full Text] [Related]
23. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261 [TBL] [Abstract][Full Text] [Related]
25. Fingolimod: a novel immunosuppressant for multiple sclerosis. Brown BA; Kantesaria PP; McDevitt LM Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617 [TBL] [Abstract][Full Text] [Related]
26. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Cohen BA; Rivera VM Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658 [TBL] [Abstract][Full Text] [Related]
27. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy. Freedman MS Eur J Neurol; 2014 Mar; 21(3):377-87, e18-20. PubMed ID: 24237582 [TBL] [Abstract][Full Text] [Related]
28. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies]. Ouallet JC Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382 [TBL] [Abstract][Full Text] [Related]
29. [Fingolimod - a new immunomodulator]. Friedrich FW; Eschenhagen T Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964 [TBL] [Abstract][Full Text] [Related]
31. Indirect comparison: relative risk fallacies and odds solution. Eckermann S; Coory M; Willan AR J Clin Epidemiol; 2009 Oct; 62(10):1031-6. PubMed ID: 19179043 [TBL] [Abstract][Full Text] [Related]
32. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. Tsivgoulis G; Katsanos AH; Mavridis D; Grigoriadis N; Dardiotis E; Heliopoulos I; Papathanasopoulos P; Karapanayiotides T; Kilidireas C; Hadjigeorgiou GM; Voumvourakis K; PLoS One; 2016; 11(9):e0163296. PubMed ID: 27684943 [TBL] [Abstract][Full Text] [Related]
33. Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mitsikostas DD; Goodin DS Mult Scler Relat Disord; 2017 Nov; 18():109-116. PubMed ID: 29141791 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic advances: beta-interferon for multiple sclerosis. Clark W J Clin Pharm Ther; 1996 Aug; 21(4):195-9. PubMed ID: 8933292 [TBL] [Abstract][Full Text] [Related]
35. What's in placebos: who knows? Analysis of randomized, controlled trials. Golomb BA; Erickson LC; Koperski S; Sack D; Enkin M; Howick J Ann Intern Med; 2010 Oct; 153(8):532-5. PubMed ID: 20956710 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. Tong J; Zou Q; Chen Y; Liao X; Chen R; Ma L; Zhang D; Li Q Neurol Sci; 2021 May; 42(5):1687-1695. PubMed ID: 33523319 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of the Treatments Used in Multiple Sclerosis: From Meta-analysis to Number Needed to Treat. García-Ruiz AJ; Izquierdo-Ayuso G; Navarro-Mascarell G; Montesinos-Gálvez AC; Martos-Crespo F; Jódar-Sánchez F; Correa M; García-Agua Soler N Clin Neuropharmacol; 2017; 40(1):37-42. PubMed ID: 27941528 [TBL] [Abstract][Full Text] [Related]
38. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Goodin DS; Biermann LD; Bohlega S; Boiko A; Chofflon M; Gebeily S; Gouider R; Havrdova E; Jakab G; Karabudak R; Karussis D; Miller A; Pakdaman H; Selmaj K; Sharief M; Curr Med Res Opin; 2007 Nov; 23(11):2823-32. PubMed ID: 17908370 [TBL] [Abstract][Full Text] [Related]